List of Tables
Table 1. Global Secondary Hyperparathyroidism Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Secondary Hyperparathyroidism Drug Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Secondary Hyperparathyroidism Drug Market Competitive Situation by Manufacturers in 2024
Table 4. Global Secondary Hyperparathyroidism Drug Sales (K Pcs) of Key Manufacturers (2020-2025)
Table 5. Global Secondary Hyperparathyroidism Drug Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Secondary Hyperparathyroidism Drug Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Secondary Hyperparathyroidism Drug Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Secondary Hyperparathyroidism Drug Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Secondary Hyperparathyroidism Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Secondary Hyperparathyroidism Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Secondary Hyperparathyroidism Drug, Product Type & Application
Table 12. Global Key Manufacturers of Secondary Hyperparathyroidism Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Secondary Hyperparathyroidism Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Secondary Hyperparathyroidism Drug as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Secondary Hyperparathyroidism Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Secondary Hyperparathyroidism Drug Sales by Region (2020-2025) & (K Pcs)
Table 18. Global Secondary Hyperparathyroidism Drug Sales Market Share by Region (2020-2025)
Table 19. Global Secondary Hyperparathyroidism Drug Sales by Region (2026-2031) & (K Pcs)
Table 20. Global Secondary Hyperparathyroidism Drug Sales Market Share by Region (2026-2031)
Table 21. Global Secondary Hyperparathyroidism Drug Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Secondary Hyperparathyroidism Drug Revenue Market Share by Region (2020-2025)
Table 23. Global Secondary Hyperparathyroidism Drug Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Secondary Hyperparathyroidism Drug Revenue Market Share by Region (2026-2031)
Table 25. North America Secondary Hyperparathyroidism Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Secondary Hyperparathyroidism Drug Sales by Country (2020-2025) & (K Pcs)
Table 27. North America Secondary Hyperparathyroidism Drug Sales by Country (2026-2031) & (K Pcs)
Table 28. North America Secondary Hyperparathyroidism Drug Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Secondary Hyperparathyroidism Drug Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Secondary Hyperparathyroidism Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Secondary Hyperparathyroidism Drug Sales by Country (2020-2025) & (K Pcs)
Table 32. Europe Secondary Hyperparathyroidism Drug Sales by Country (2026-2031) & (K Pcs)
Table 33. Europe Secondary Hyperparathyroidism Drug Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Secondary Hyperparathyroidism Drug Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Secondary Hyperparathyroidism Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Secondary Hyperparathyroidism Drug Sales by Region (2020-2025) & (K Pcs)
Table 37. Asia Pacific Secondary Hyperparathyroidism Drug Sales by Region (2026-2031) & (K Pcs)
Table 38. Asia Pacific Secondary Hyperparathyroidism Drug Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Secondary Hyperparathyroidism Drug Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Secondary Hyperparathyroidism Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Secondary Hyperparathyroidism Drug Sales by Country (2020-2025) & (K Pcs)
Table 42. Latin America Secondary Hyperparathyroidism Drug Sales by Country (2026-2031) & (K Pcs)
Table 43. Latin America Secondary Hyperparathyroidism Drug Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Secondary Hyperparathyroidism Drug Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Secondary Hyperparathyroidism Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Secondary Hyperparathyroidism Drug Sales by Country (2020-2025) & (K Pcs)
Table 47. Middle East and Africa Secondary Hyperparathyroidism Drug Sales by Country (2026-2031) & (K Pcs)
Table 48. Middle East and Africa Secondary Hyperparathyroidism Drug Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Secondary Hyperparathyroidism Drug Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Secondary Hyperparathyroidism Drug Sales (K Pcs) by Type (2020-2025)
Table 51. Global Secondary Hyperparathyroidism Drug Sales (K Pcs) by Type (2026-2031)
Table 52. Global Secondary Hyperparathyroidism Drug Sales Market Share by Type (2020-2025)
Table 53. Global Secondary Hyperparathyroidism Drug Sales Market Share by Type (2026-2031)
Table 54. Global Secondary Hyperparathyroidism Drug Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Secondary Hyperparathyroidism Drug Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Secondary Hyperparathyroidism Drug Revenue Market Share by Type (2020-2025)
Table 57. Global Secondary Hyperparathyroidism Drug Revenue Market Share by Type (2026-2031)
Table 58. Global Secondary Hyperparathyroidism Drug Price (USD/Pcs) by Type (2020-2025)
Table 59. Global Secondary Hyperparathyroidism Drug Price (USD/Pcs) by Type (2026-2031)
Table 60. Global Secondary Hyperparathyroidism Drug Sales (K Pcs) by Application (2020-2025)
Table 61. Global Secondary Hyperparathyroidism Drug Sales (K Pcs) by Application (2026-2031)
Table 62. Global Secondary Hyperparathyroidism Drug Sales Market Share by Application (2020-2025)
Table 63. Global Secondary Hyperparathyroidism Drug Sales Market Share by Application (2026-2031)
Table 64. Global Secondary Hyperparathyroidism Drug Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Secondary Hyperparathyroidism Drug Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Secondary Hyperparathyroidism Drug Revenue Market Share by Application (2020-2025)
Table 67. Global Secondary Hyperparathyroidism Drug Revenue Market Share by Application (2026-2031)
Table 68. Global Secondary Hyperparathyroidism Drug Price (USD/Pcs) by Application (2020-2025)
Table 69. Global Secondary Hyperparathyroidism Drug Price (USD/Pcs) by Application (2026-2031)
Table 70. Deltanoid Pharmaceuticals Inc Company Information
Table 71. Deltanoid Pharmaceuticals Inc Description and Business Overview
Table 72. Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 73. Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Product
Table 74. Deltanoid Pharmaceuticals Inc Recent Developments/Updates
Table 75. EA Pharma Co Ltd Company Information
Table 76. EA Pharma Co Ltd Description and Business Overview
Table 77. EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 78. EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Product
Table 79. EA Pharma Co Ltd Recent Developments/Updates
Table 80. Lupin Ltd Company Information
Table 81. Lupin Ltd Description and Business Overview
Table 82. Lupin Ltd Secondary Hyperparathyroidism Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 83. Lupin Ltd Secondary Hyperparathyroidism Drug Product
Table 84. Lupin Ltd Recent Developments/Updates
Table 85. Mitsubishi Tanabe Pharma Corp Company Information
Table 86. Mitsubishi Tanabe Pharma Corp Description and Business Overview
Table 87. Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 88. Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Product
Table 89. Mitsubishi Tanabe Pharma Corp Recent Developments/Updates
Table 90. OPKO Health Inc Company Information
Table 91. OPKO Health Inc Description and Business Overview
Table 92. OPKO Health Inc Secondary Hyperparathyroidism Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 93. OPKO Health Inc Secondary Hyperparathyroidism Drug Product
Table 94. OPKO Health Inc Recent Developments/Updates
Table 95. Takeda Company Information
Table 96. Takeda Description and Business Overview
Table 97. Takeda Secondary Hyperparathyroidism Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 98. Takeda Secondary Hyperparathyroidism Drug Product
Table 99. Takeda Recent Developments/Updates
Table 100. Key Raw Materials Lists
Table 101. Raw Materials Key Suppliers Lists
Table 102. Secondary Hyperparathyroidism Drug Distributors List
Table 103. Secondary Hyperparathyroidism Drug Customers List
Table 104. Secondary Hyperparathyroidism Drug Market Trends
Table 105. Secondary Hyperparathyroidism Drug Market Drivers
Table 106. Secondary Hyperparathyroidism Drug Market Challenges
Table 107. Secondary Hyperparathyroidism Drug Market Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
Table 111. Authors List of This Report
List of Figures
Figure 1. Product Picture of Secondary Hyperparathyroidism Drug
Figure 2. Global Secondary Hyperparathyroidism Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Secondary Hyperparathyroidism Drug Market Share by Type: 2024 & 2031
Figure 4. Evocalcet Product Picture
Figure 5. LNP-1892 Product Picture
Figure 6. AJT-240 Product Picture
Figure 7. Cinacalcet Hydrochloride Product Picture
Figure 8. CTA-091 Product Picture
Figure 9. Others Product Picture
Figure 10. Global Secondary Hyperparathyroidism Drug Market Value by Application (2020-2031) & (US$ Million)
Figure 11. Global Secondary Hyperparathyroidism Drug Market Share by Application: 2024 & 2031
Figure 12. Hospital
Figure 13. Clinic
Figure 14. Others
Figure 15. Global Secondary Hyperparathyroidism Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Secondary Hyperparathyroidism Drug Market Size (2020-2031) & (US$ Million)
Figure 17. Global Secondary Hyperparathyroidism Drug Sales (2020-2031) & (K Pcs)
Figure 18. Global Secondary Hyperparathyroidism Drug Average Price (USD/Pcs) & (2020-2031)
Figure 19. Secondary Hyperparathyroidism Drug Report Years Considered
Figure 20. Secondary Hyperparathyroidism Drug Sales Share by Manufacturers in 2024
Figure 21. Global Secondary Hyperparathyroidism Drug Revenue Share by Manufacturers in 2024
Figure 22. Global 5 and 10 Largest Secondary Hyperparathyroidism Drug Players: Market Share by Revenue in Secondary Hyperparathyroidism Drug in 2024
Figure 23. Secondary Hyperparathyroidism Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 24. Global Secondary Hyperparathyroidism Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 25. North America Secondary Hyperparathyroidism Drug Sales Market Share by Country (2020-2031)
Figure 26. North America Secondary Hyperparathyroidism Drug Revenue Market Share by Country (2020-2031)
Figure 27. U.S. Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Canada Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Europe Secondary Hyperparathyroidism Drug Sales Market Share by Country (2020-2031)
Figure 30. Europe Secondary Hyperparathyroidism Drug Revenue Market Share by Country (2020-2031)
Figure 31. Germany Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. France Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. U.K. Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Italy Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Russia Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Asia Pacific Secondary Hyperparathyroidism Drug Sales Market Share by Region (2020-2031)
Figure 37. Asia Pacific Secondary Hyperparathyroidism Drug Revenue Market Share by Region (2020-2031)
Figure 38. China Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Japan Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. South Korea Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. India Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Australia Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Taiwan Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Indonesia Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Thailand Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Malaysia Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Philippines Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Latin America Secondary Hyperparathyroidism Drug Sales Market Share by Country (2020-2031)
Figure 49. Latin America Secondary Hyperparathyroidism Drug Revenue Market Share by Country (2020-2031)
Figure 50. Mexico Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Brazil Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Argentina Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Middle East and Africa Secondary Hyperparathyroidism Drug Sales Market Share by Country (2020-2031)
Figure 54. Middle East and Africa Secondary Hyperparathyroidism Drug Revenue Market Share by Country (2020-2031)
Figure 55. Turkey Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. Saudi Arabia Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. U.A.E Secondary Hyperparathyroidism Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. Global Sales Market Share of Secondary Hyperparathyroidism Drug by Type (2020-2031)
Figure 59. Global Revenue Market Share of Secondary Hyperparathyroidism Drug by Type (2020-2031)
Figure 60. Global Secondary Hyperparathyroidism Drug Price (USD/Pcs) by Type (2020-2031)
Figure 61. Global Sales Market Share of Secondary Hyperparathyroidism Drug by Application (2020-2031)
Figure 62. Global Revenue Market Share of Secondary Hyperparathyroidism Drug by Application (2020-2031)
Figure 63. Global Secondary Hyperparathyroidism Drug Price (USD/Pcs) by Application (2020-2031)
Figure 64. Secondary Hyperparathyroidism Drug Value Chain
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
